Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

79.45 USD -0.14 (-0.18%)
Official Closing Price Updated: 7:29 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 742,100
Open 79.51
Bid (Size) 78.97 (7)
Ask (Size) 79.90 (1)
Prev. Close 79.59
Today's Range 79.03 - 80.59
52wk Range 71.35 - 131.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and P
Normal Progression of Bone Age with Chronological Age Over 60 Months with Vosoritide for Children with Achondroplasia 
From PR Newswire
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29,... 
From PR Newswire

Performance

YTD
-7.94%
-7.94%
1 Month
+1.18%
+1.18%
3 Month
-7.37%
-7.37%
6 Month
+1.98%
+1.98%
1 Year
-14.75%
-14.75%

More News

Read More
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
From PR Newswire
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
From PR Newswire
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
From PR Newswire
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
From PR Newswire
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
From PR Newswire
First Trust Lunt U.S. Factor Rotation ETF Experiences Big Outflow
Tags ETFs
From ETF Channel
BioMarin Pharmaceutical Moves Up In Market Cap Rank, Passing Howmet Aerospace
Tags Stocks
From Market News Video
Noteworthy Wednesday Option Activity: BMRN, PLCE, KEX
Tags Stocks
From Market News Video
PBE's Holdings Could Mean 19% Gain Potential
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.